Compare · AGL vs FMS
AGL vs FMS
Side-by-side comparison of agilon health inc. (AGL) and Fresenius Medical Care AG (FMS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and FMS operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $13.13B, about 8.1x AGL ($1.61B).
- AGL has been more active in the news (8 items in the past 4 weeks vs 7 for FMS).
- AGL has more recent analyst coverage (25 ratings vs 23 for FMS).
- Company
- agilon health inc.
- Fresenius Medical Care AG
- Price
- -
- -
- Market cap
- $1.61B
- $13.13B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 8
- 7
- Recent ratings
- 25
- 23
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest AGL
- agilon health to Participate in Upcoming Conferences
- Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 17 shares, decreasing direct ownership by 0.12% to 14,152 units (SEC Form 4) (withholding tax)
- Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.
- agilon health upgraded by Citigroup with a new price target
- SEC Form 10-Q filed by agilon health inc.
- agilon health inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Chief Legal Officer Zamore Denise covered exercise/tax liability with 37 shares, decreasing direct ownership by 0.06% to 66,075 units (SEC Form 4) to satisfy withholding tax
- agilon health downgraded by Citigroup with a new price target
- agilon health inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest FMS
- Amendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery
- Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda
- Fresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patients
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical downgraded by BNP Paribas Exane with a new price target